SS Innovations Posts Record Q2 Revenue of $13.9M, Up 39% YoY
SSII sits 20% above its 52-week low of $3.11 on light trading volume (0.3× avg).
Summary
SS Innovations reported record Q2 2026 revenue of $13.9 million, up 39.4% year-over-year, driven by strong SSi Mantra robotic system sales. Gross margin declined to 50.9% from 59.1% a year ago, and net loss widened to $2.7 million from $0.3 million, reflecting higher R&D and stock compensation. The company installed 30 systems in the quarter, bringing the cumulative base to 224 across twelve countries. Management expects FDA 510(k) review completion by end of Q1 2027 and CE marking by end of 2026, which are key catalysts for U.S. and EU market entry. Cash stands at $13.6 million with no long-term debt, but the going concern warning from the 10-Q remains a risk. This follows the CFO transition completed August 3 and the $50M ATM offering launched in June.
At the time of this announcement, SSII was trading at $3.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $738.5M. The 52-week trading range was $3.11 to $10.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.